BioMarin Pharmaceutical vs Royalty Pharma
BMRN and RPRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BMRN and RPRX compare
Royalty Pharma is the larger company, worth 3.6 times as much as BioMarin Pharmaceutical ($39.9B against $11.1B).
On earnings, Royalty Pharma is cheaper: it trades at 48.8× trailing earnings, against 151× for BioMarin Pharmaceutical.
Royalty Pharma grew revenue faster over the last twelve months (11.4% versus 11.2% for BioMarin Pharmaceutical).
Royalty Pharma keeps more of each dollar of sales as profit, with a net margin of 25.7% compared with 2.1% at BioMarin Pharmaceutical.
Royalty Pharma pays a dividend yielding 1.7%; BioMarin Pharmaceutical does not pay one.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BMRN | RPRX |
|---|---|---|
| Size and price | ||
| Market cap | $11.1B | $39.9B |
| Share price | $57.23 | $69.31 |
| Change, 1 year | 3.5% | 75.1% |
| Change, 5 years | −37.4% | 66.8% |
| Beta (5Y) | 0.59 | 0.41 |
| Employees | 3,221 | 100 |
| StockData Score | ||
| Total score | 8 | 8 |
| Valuation score | 1 (better) | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 2 (better) | 1 |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/E | 151× | 48.8× (better) |
| P/S | 3.3× (better) | 15.2× |
| P/B | 1.8× | – |
| EV/EBITDA | 47.6× | 34.0× (better) |
| P/FCF | 15.0× | – |
| PEG | 4.44 | 0.30 (better) |
| FCF yield | 6.7% | – |
| Fair value | $30.00 | $43.25 |
| Margin of safety | −90.8% | −60.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 11.2% | 11.4% (better) |
| Revenue growth, 5Y average | 11.6% (better) | 2.3% |
| Net income growth (TTM) | −88.9% | −12.0% (better) |
| EPS growth (TTM) | −88.7% | −12.9% (better) |
| EPS growth, 5Y average | −16.7% | 6.2% (better) |
| Profitability | ||
| Gross margin | 76.1% | – |
| Operating margin | 4.4% | 57.1% (better) |
| Net margin | 2.1% | 25.7% (better) |
| FCF margin | 21.7% | – |
| Return on equity | 1.2% | – |
| Return on invested capital | 1.0% | – |
| Financial health | ||
| Debt / equity | 0.66 | – |
| Net debt / EBITDA | 10.96 | 5.38 (better) |
| Interest coverage | 2.0× | 4.0× (better) |
| Current ratio | 2.39 (better) | 1.29 |
| Altman Z-score | 1.84 | 3.06 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 1.7% |
| Buyback yield | – | 0.66% |
| Shareholder yield | 0.00% | 2.3% (better) |
| Ownership | ||
| Held by institutions | 101% | 63.8% |
| Held by insiders | 0.52% | 22.6% |
| Insider net buying, 12 months | −$4.3M (better) | −$82.2M |
| Superinvestors holding | 1 | 2 (better) |
| Short interest, % of float | 7.3% | 2.9% |
Go deeper
- BMRN stock overview
- BMRN income statement
- BMRN valuation and score
- RPRX stock overview
- RPRX income statement
- RPRX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.